% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Jun 4, 2013 6:49 PM Flag

    OT: ficltuzumab

    It might be prudent to pay attention to the AVEO re-structuring conference call tomorrow AM. They are expected to announce development plans for ficla, a MAB of the HGF/c-Met pathway. Whatever strategy they employ, it'll be interesting to see how they intend to dance with Cabo as an obvious competitor in the c-Met space. They are currently fully enrolled in a P2 in NSCLC comparing gefitinib plus ficla to gefitinib monotherapy. Early results have been favorable, for all the same rationale that supports Cabo.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$
      For those following the progress of other modalities of cMET inhibition.
      The following posted in the JCO May 28th, 2013...

      "Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib"

6.30+0.07(+1.12%)May 26 4:00 PMEDT